JanOne Readies Clinical Supply of Lead Product Candidate JAN101 for Distribution to Phase 2b Trial Sites
JanOne Inc. (Nasdaq: JAN) has announced that its clinical packaging partner, Xerimis, has received the bottled clinical batch of JAN101 for the Phase 2b trial aimed at treating Peripheral Artery Disease (PAD). The drug is set for distribution to clinical sites across the U.S. Following positive Phase 1 and 2a results, which indicated pain reduction among PAD patients, the company anticipates that JAN101 could yield a multibillion-dollar market opportunity if approved. JanOne aims to provide a non-addictive alternative for the 8.5 million Americans suffering from PAD.
- Successful transition to Phase 2b trial with clinical supply ready for distribution.
- Positive outcomes in early Phase 1 and 2a trials indicating pain reduction in PAD patients.
- Potential for a multibillion-dollar revenue stream if JAN101 gains FDA approval.
- None.
LAS VEGAS, June 23, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that its clinical packaging partner Xerimis has received the bottled clinical batch of JAN101 for the upcoming Phase 2b trial for treating Peripheral Artery Disease (PAD) and is readying the supply for labeling and distribution to clinical sites throughout the U.S.
"We are pleased to report that our clinical supply of JAN101 is now ready for near-term release to our expected clinical trial sites in the upcoming Phase 2 clinical trial," said Tony Isaac, President and Chief Executive Officer of JanOne. "We are fully prepared and look forward to FDA approval of our new protocol."
JAN101 is intended to address the 8.5 million Americans who may have PAD. One of the more encouraging outcomes from patients who participated in early Phase 1 and Phase 2a trials of JAN101 was a reported reduction in associated PAD pain. According to a Stanford University research study, up to
About JanOne
JanOne (Nasdaq: JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate, JAN101, is for potentially treating peripheral artery disease ("PAD"), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and the Company is currently in preparations for Phase 2b trials. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions, and neuropathic pain. For more information, visit www.janone.com.
Forward-Looking and Cautionary Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In accordance with the safe harbor provisions of this Act, statements contained herein that look forward in time that include everything other than historical information, including statements relating to the commencement of the upcoming Phase 2b trials, the number of Americans who may have PAD, whether JAN101 will benefit the medical community, and the potential revenue stream if JAN101 is approved by the FDA. These forward-looking statements can be identified by terminology such as "will," "aims," "upcoming," "may," "expects," "expected," "potential," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. JanOne may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC") on Forms 10-K and 10-Q, Current Reports on Form 8-K, in its annual report to stockholders, in press releases, and other written materials and in oral statements made by its officers, directors or employees to third parties. There can be no assurance that such statements will prove to be accurate and there are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the company, including, but not limited to, plans and objectives of management for future operations or products, the market acceptance or future success of our products, and our future financial performance. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report on Form 10-K for the fiscal year ended January 2, 2021 and other SEC filings (available at http://www.sec.gov). JanOne undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
Investor Relations & Media Contact
IR@Janone.com
1 (800) 400-2247
1 https://pubmed.ncbi.nlm.nih.gov/30922747/
View original content to download multimedia:http://www.prnewswire.com/news-releases/janone-readies-clinical-supply-of-lead-product-candidate-jan101-for-distribution-to-phase-2b-trial-sites-301318441.html
SOURCE JanOne Inc.
FAQ
What is JAN101 and what condition does it aim to treat?
What are the results from the early trials of JAN101?
What is the potential market size for JAN101 if approved?
When is the Phase 2b trial for JAN101 expected to begin?
What is the significance of JAN101 for pain management?
